Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma

References

• Wood GW, Morantz RA. In vitro reversal of depressed -lymphocyte function in the peripheral blood of brain tumor patients. J. Natl Cancer Inst.68(1), 27–33 (1982).
   PubMedGoogle Scholar
• Wood GW, Morantz RA. Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells. J. Neurooncol.1(2), 87–94 (1983).
   PubMedGoogle Scholar
• Yamasaki T, Handa H, Yamashita J, Namba Y, Hanaoka M. Characteristic immunological responses to an experimental mouse brain tumor. Cancer Res.43(10), 4610–4617 (1983).
   PubMedGoogle Scholar
• Grauer O, Poschl P, Lohmeier A, Adema GJ, Bogdahn U. Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome -cell inhibition by glioma-associated TG-β2. J. Neurooncol.82(2), 151–161 (2006).
   PubMedGoogle Scholar
• Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-β in growth, motility, angiogenesis, and immune escape. Microsc. Res. Tech.52(4), 401–410 (2001).
   PubMed Web of Science ®Google Scholar
• Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res. Brain Res. Rev.21(2), 128–151 (1995).
   PubMed Web of Science ®Google Scholar
• Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin CH. Transforming growth factor-β1, -β2, and -β3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J. Biol. Chem.267(27), 19482–19488 (1992).
   PubMed Web of Science ®Google Scholar
• Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2. J. Neurosurg.71(2), 211–217 (1989).
   PubMed Web of Science ®Google Scholar
• Lauro GM, Di Lorenzo N, Grossi M, Maleci A, Guidetti B. Prostaglandin E2 as an immunomodulating factor released in vitro by human glioma cells. Acta Neuropathol.69(3–4), 278–282 (1986).
   PubMed Web of Science ®Google Scholar
• Nakano Y, Kuroda E, Kito T, Yokota A, Yamashita U. Induction of macrophagic prostaglandin E2 synthesis by glioma cells. J. Neurosurg.104(4), 574–582 (2006).
   PubMedGoogle Scholar
• Ito A, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol. Immunother.50(10), 515–522 (2001).
   PubMed Web of Science ®Google Scholar
• Prins RM, Liau LM. Cellular immunity and immunotherapy of brain tumors. Front. Biosci.9, 3124–3136 (2004).
   PubMed Web of Science ®Google Scholar
• Wiendl H, Mitsdoerffer M, Hofmeister V et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol.168(9), 4772–4780 (2002).
   PubMed Web of Science ®Google Scholar
• Wiendl H, Mitsdoerffer M, Weller M. Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Semin. Cancer Biol.13(5), 343–351 (2003).
   PubMed Web of Science ®Google Scholar
• El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+ CD25+ regulatory T-cells in mice with experimental brain tumors. J. Neurosurg.105(3), 430–437 (2006).
   PubMed Web of Science ®Google Scholar
• El Andaloussi A, Lesniak MS. An increase in CD4+ CD25+ FOXP3+ regulatory T-cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-oncology8(3), 234–243 (2006).
   PubMed Web of Science ®Google Scholar
• El Andaloussi A, Lesniak MS. CD4(+) CD25(+) FoxP3(+) T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J. Neurooncol.83(2), 145–152 (2007).
   PubMed Web of Science ®Google Scholar
• El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia54(6), 526–535 (2006).
   PubMed Web of Science ®Google Scholar
• Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res.66(6), 3294–3302 (2006).
   PubMed Web of Science ®Google Scholar
• Fecci PE, Sweeney AE, Grossi PM et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin. Cancer Res.12(14 Pt 1), 4294–4305 (2006).
   PubMed Web of Science ®Google Scholar
• Grauer OM, Nierkens S, Bennink E et al. CD4+ FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int. J. Cancer121(1), 95–105 (2007).
   PubMed Web of Science ®Google Scholar
• Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-oncology8(3), 261–279 (2006).
   PubMed Web of Science ®Google Scholar
• Learn CA, Fecci PE, Schmittling RJ et al. Profiling of CD4+, CD8+, and CD4+ CD25+ CD45RO+ FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin. Cancer Res.12(24), 7306–7315 (2006).
   PubMedGoogle Scholar
• Barnett JA, Urbauer DL, Murray GI, Fuller GN, Heimberger AB. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin. Cancer Res.13(12), 3559–3567 (2007).
   PubMed Web of Science ®Google Scholar
• Kumarakulasingham M, Rooney PH, Dundas SR et al. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin. Cancer Res.11(10), 3758–3765 (2005).
   PubMed Web of Science ®Google Scholar
• Downie D, McFadyen MC, Rooney PH et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin. Cancer Res.11(20), 7369–7375 (2005).
   PubMed Web of Science ®Google Scholar
• McFadyen MC, Cruickshank ME, Miller ID et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br. J. Cancer85(2), 242–246 (2001).
   PubMed Web of Science ®Google Scholar
• Gribben JG, Ryan DP, Boyajian R et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin. Cancer Res.11(12), 4430–4436 (2005).
   PubMed Web of Science ®Google Scholar
• Liu G, Yu JS, Zeng G et al. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J. Immunother. (1997)27(3), 220–226 (2004).
   PubMed Web of Science ®Google Scholar
• Eguchi J, Hatano M, Nishimura F et al. Identification of interleukin-13 receptor α2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res.66(11), 5883–5891 (2006).
   PubMedGoogle Scholar
• Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain. Clin. Cancer Res.8(9), 2851–2855 (2002).
   PubMed Web of Science ®Google Scholar
• Fossum B, Gedde-Dahl 3rd T, Breivik J et al. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp). Int. J. Cancer56(1), 40–45 (1994).
   PubMed Web of Science ®Google Scholar
• Fenton RG, Keller CJ, Hanna N, Taub DD. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J. Natl Cancer Inst.87(24), 1853–1861 (1995).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Hlatky R, Suki D et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res.11(4), 1462–1466 (2005).
   PubMed Web of Science ®Google Scholar
• Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res.63(20), 6962–6970 (2003).
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res.51(8), 2164–2172 (1991).
   PubMed Web of Science ®Google Scholar
• Bigner SH, Humphrey PA, Wong AJ et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res.50(24), 8017–8022 (1990).
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Wong AJ, Vogelstein B et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res.48(8), 2231–2238 (1988).
   PubMed Web of Science ®Google Scholar
• Libermann TA, Nusbaum HR, Razon N et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature313(5998), 144–147 (1985).
   PubMed Web of Science ®Google Scholar
• Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl Acad. Sci. USA84(19), 6899–903 (1987).
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res.57(18), 4130–4140 (1997).
   PubMed Web of Science ®Google Scholar
• Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl Acad. Sci. USA87(21), 8602–8606 (1990).
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, Longo N, Hamid ML et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene9(8), 2313–2320 (1994).
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res.57(8), 1419–1424 (1997).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Crotty LE, Archer GE et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res.9(11), 4247–4254 (2003).
   PubMed Web of Science ®Google Scholar
• Ciesielski MJ, Kazim AL, Barth RF, Fenstermaker RA. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol. Immunother.54(2), 107–119 (2005).
   PubMedGoogle Scholar
• Heimberger AB, Hussain SF, Aldape K et al. ASCO annual meeting proceedings part I. J. Clin. Oncol.24(18S)(Suppl.), 2529 (2006).
   Google Scholar
• Sampson JH, Alsape KD, Gilbert MR et al. 2007 ASCO annual meeting proceedings part I. J. Clin. Oncol.25(18S)(Suppl.), 2020 (2007).
   Google Scholar
• Goldman B. Taming a mutinous mutant: an errant receptor becomes a prime cancer target. J. Natl Cancer Inst.99(7), 504–505 (2007).
   PubMedGoogle Scholar